Cargando…
Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892364/ https://www.ncbi.nlm.nih.gov/pubmed/35252744 http://dx.doi.org/10.1093/rap/rkac012 |
| _version_ | 1784662150536495104 |
|---|---|
| author | Sugiyama, Masafumi Okuda, Saki Hirooka, Yasuaki |
| author_facet | Sugiyama, Masafumi Okuda, Saki Hirooka, Yasuaki |
| author_sort | Sugiyama, Masafumi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8892364 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88923642022-03-04 Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis Sugiyama, Masafumi Okuda, Saki Hirooka, Yasuaki Rheumatol Adv Pract Letter to the Editor (Case report) Oxford University Press 2022-02-16 /pmc/articles/PMC8892364/ /pubmed/35252744 http://dx.doi.org/10.1093/rap/rkac012 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Letter to the Editor (Case report) Sugiyama, Masafumi Okuda, Saki Hirooka, Yasuaki Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title | Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title_full | Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title_fullStr | Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title_full_unstemmed | Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title_short | Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| title_sort | minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis |
| topic | Letter to the Editor (Case report) |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892364/ https://www.ncbi.nlm.nih.gov/pubmed/35252744 http://dx.doi.org/10.1093/rap/rkac012 |
| work_keys_str_mv | AT sugiyamamasafumi minimalchangenephroticsyndromeduetocertolizumabpegolanantitumornecrosisfactoralphamonoclonalantibodyfortreatmentofrheumatoidarthritis AT okudasaki minimalchangenephroticsyndromeduetocertolizumabpegolanantitumornecrosisfactoralphamonoclonalantibodyfortreatmentofrheumatoidarthritis AT hirookayasuaki minimalchangenephroticsyndromeduetocertolizumabpegolanantitumornecrosisfactoralphamonoclonalantibodyfortreatmentofrheumatoidarthritis |